The article leads one to determine that regular treatment every two days or three times per week is more effective than less frequent treatment plans.
It reads as follows:
The results of monotherapy with NBUVB have been better in Asian skin. Approximately three-quarters of patients in the series by Kanwar et al. achieved greater than 75% to complete repigmentation after NBUVB treatment for a maximum period of 1 year. The mean duration of disease was significantly shorter in those who had marked to complete pigmentation compared with those who had poorer response. As with any treatment modality for vitiligo, the best results were observed in lesions on the face and neck, followed by the proximal limbs and trunk. Perifollicular pigmentation was the most common type of initial repigmentation that was observed in approximately three-quarters of patients.
Brazzelli et al. have studied the effect of NBUVB in vitiligo and the influence of body sites, age of the patients and duration of disease on clinical response.Complete repigmentation was more commonly observed in lesions located on the face, neck and trunk in decreasing order of frequency (68, 57.9 and 50%, respectively). Age of the patients did not influence the response to treatment for facial lesions, while in other areas complete repigmentation was much more commonly observed in younger patients (<20 years). As far as the duration of disease is concerned, lesions over the neck, upper and lower limbs showed the best rate of complete repigmentation (83.3, 33.3 and 28.5%, respectively) in patients with disease of recent onset (<2 years), while for the lesions over the face, longstanding vitiligo patients responded better. The authors recommend early treatment, as the best results were achieved by young patients with recent-onset vitiligo.
In a randomized, controlled, side-to-side comparison study, mean improvement in the NBUVB was 42.9% compared with 3.3% in the untreated control side, with the severity of disease having been assessed by Vitiligo Area Scoring Index (VASI). Response to treatment varied greatly between different anatomic sites, with the best response seen over the lower extremities and worst response on the feet. Whereas all patients did not receive treatment for their face, 37.5% of those who In a recent large, open, prospective study from India, only approximately a quarter of patients could achieve more than 75% repigmentation. This poor result in Indian patients can be attributed to lower initial dose and twice-weekly treatment. In those patients who had significant pigmentation, it was attributed to good compliance, a greater number of treatments and increasing cumulative dose. Although initial repigmentation was darker, good color matching could be achieved with continued treatment.
Read more at http://www.medscape.org/viewarticle/725936_6